Eli Lilly gets a short cut at FDA for abemaciclib; Calyxt files for $100M IPO
⇨ Looking to play catch-up with the leaders in the CDK 4/6 cancer field, Eli Lilly scored the inside track at the FDA for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
